Vortioxetine (Brintellix) approved for MDD

The FDA has approved vortioxetine (Brintellix) for the treatment of major depressive disorder (MDD). Brintellix is a novel antidepressant thought to work by enhancing serotonergic acitivty as a serotonin (5-HT) reuptake inhibitor and agonist of the 5-HT1A receptor, among other mechanisms.

Current Subscribers

Purchase a subscription

To view the full content, you need to purchase a subscription.